trending Market Intelligence /marketintelligence/en/news-insights/trending/dCXLaKbJbkKkN3YsyrT4FQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Entasis Therapeutics to sell up to $20M of common shares to private fund

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Entasis Therapeutics to sell up to $20M of common shares to private fund

Entasis Therapeutics Holdings Inc. agreed to sell common shares for up to $20 million to Chicago-based private fund Aspire Capital Fund LLC over a period of 30 months.

Under the agreement, Waltham, Mass.-based biotechnology company Entasis can sell up to 2,626,165 common shares to Aspire Capital, including 104,167 shares issued to the asset management firm as consideration for entering into the agreement.

Entasis will require shareholders' approval to sell more than 19.99% of the company's outstanding shares to Aspire Capital. However, if all shares under the purchase agreement are sold for an average price equal to or greater than $5.75, the approval restriction will not apply.

Entasis and Aspire Capital did not hire any agent, broker or financial adviser for the deal.